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Abstract
Obstructive sleep apnea syndrome (OSAS) is a well established risk factor for
hypertension and is associated with an enhanced sympathetic activity. In this series of
studies we described the pathophysiological changes of blood pressure and autonomous
nervous system activity in patients with OSAS.
We demonstrated that CPAP can modulate the autonomous nervous activity by reducing
the sympathetic discharge as seen by a reduction of blood pressure variability.
In a cohort of 78 patients (76.9%male, 49%hypertensive) a 2 week autoset-CPAP
treatment determined a reduction of systolic BPV (5.3±4.9 vs 4.2±3.4 mmHg, p=0.047)
and pulse rate (78.0±14.5 vs 75.5±15.8 bpm, p=0.032). 
An effect on blood pressure, pulse rate and blood pressure variability depends also on
CPAP adherence and, particularly in obese subjects, on pressure's loading effect on the
respiratory system. We studied 16 patients (13males, 47(10)years, BMI 38.5(5.8)kg/m2).
Blood pressure was measured continuously with a Finapres device at increasing CPAP
pressure levels. BP and BPV increased with incremental CPAP (systolic BP r=0.960,
p<0.001, diastolic BP r=0.961, p<0.001; systolic BPV r=0.662,p=0.026; diastolic BPV
r=0.886,p<0.001) and abdominal muscles activity, a surrogate marker of neuro respiratory
drive, correlated with both systolic (r=0.464,p=0.032) and diastolic BP (r=0.747,p=0.009).
As the activity of the autonomous nervous system is mediated by the catecholaminergic
system we hypothesized that the activity of Catechol-O-methyltransferase (COMT), one of
the major mammalian enzymes involved in the metabolic degradation of catecholamines,
measured during drug induced sleep endoscopy (DISE), was altered during intermittent
hypoxia in patients with OSAS.
We recruited 6 patients with OSAS who underwent DISE. During the procedure 7 blood
samples were drown for the analysis of COMT activity and catecholamines concentration
before, during and after an obstructive event. COMT analysis showed an increase of the
enzyme activity after sedation. This was more marked when propofol-induced central
apnea occurred compared to baseline (181.2 (12.8) pmol/min/mg vs 99.4 (11.1)
pmol/min/mg, p<0.05).
In this preliminary analysis we showed that the catecholaminergic system is stimulated
during DISE after apneic events. This might be due to an altered activity of COMT during
hypoxia therefore suggesting a novel pathophysiological pathway responsible of
hypertension in patients with OSAS. 
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Riassunto
La sindrome delle apnee ostruttive nel sonno (OSAS) e' un fattore di rischio per lo sviluppo
di ipertensione ed e' associata ad un'attivazione del sistema nervoso simpatico. In questa
serie di studi abbiamo dimostrato le alterazioni emodinamiche e del sistema nervoso
autonomo in pazienti con OSAS.
La terapia con pressione continua (CPAP) e' in grado di modulare l'attività del sistema
nervoso autonomo riducendo la variabilità pressoria (VP), un noto marker dell'attività
simpatica.
Sono stati reclutati 78 pazienti (76.9% maschi, 49% ipertesi) sottoposti ad un ciclo di
CPAP per due settimane. Al termine si e' osservata una riduzione della VP sistolica
(5.3±4.9 vs 4.2±3.4 mmHg, p=0.047) e della frequenza cardiaca (78.0±14.5 vs 75.5±15.8
bpm, p=0.032). 
Tali effetti della terapia con CPAP non possono prescindere dalla aderenza alla terapia
stessa oltre che da altri fattori come la pressione erogata, in particolare in soggetti obesi.
Abbiamo studiato 16 pazienti (13 maschi, eta' media 47 anni, BMI 38.5 kg/m2). La
pressione arteriosa (PA) e' stata misurata in maniera continuativa con dispositivo Finapres
a livelli crescenti di pressione nelle vie aeree. La PA e la VP aumentavano con
l'aumentare della pressione della CPAP (PA sistolica r=0.960, p<0.001, diastolica r=0.961,
p<0.001; VP sistolica  r=0.662, p=0.026; diastolica r=0.886, p<0.001) e la attività dei
muscoli respiratori accessori correlava con la PA sistolica e diastolica (r=0.464, p=0.032 e
r=0.747, p=0.009 rispettivamente).
Poiché l'attività del sistema nervoso autonomo e' mediata dalle catecolamine abbiamo
studiato l'attività della Catecol-O-metil-transferasi (COMT), uno dei più importanti enzimi
coinvolti nella degradazione delle catecolamine, in soggetti con OSAS sottoposti ad
endoscopia in sedazione (DISE) ipotizzando che l'attività enzimatica fosse alterata durante
ipossia intermittente.
Abbiamo arruolato 6 pazienti ipertesi con OSAS di grado moderato che sono stati
sottoposti a DISE durante la quale sono stati eseguiti 7 prelievi ematici seriati per il
dosaggio delle catecolamine e dell'attività di COMT prima durante e dopo una apnea
ostruttiva.
Dei pazienti arruolati 5 erano di sesso maschile, l'eta media era 48 anni e l'indice di massa
corporea medio era di 27.71 (3.42) kg/m2. L'analisi della COMT ha mostrato un aumento
dopo la sedazione in particolare in concomitanza dell'apnea centrale indotta dall'anestetico
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(181.2 (12.8) pmol/min/mg vs 99.4 (11.1) pmol/min/mg, p<0.05).
Nell'analisi preliminare di questo studio il sistema catecolaminergico appare stimolato
durante DISE dopo un'apnea. Questo e' verosimilmente dovuto all'alterata attività
dell'enzima durante ipossia il che suggerisce un nuovo meccanismo fisiopatologico per lo
sviluppo di ipertensione nei pazienti con OSAS. 
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Background
Obstructive sleep apnoea syndrome (OSAS) is a sleep disorder characterised by recurrent
episodes of upper airway obstruction during sleep and associated with recurrent cycles of
desaturation and re-oxygenation, sympathetic over-activity and intra-thoracic pressure
changes, leading to fragmentation of sleep and consequent daytime fatigue and
sleepiness. 1
Of all sleep-disordered breathing (SDB) OSAS is by far the most prevalent and should be
considered as a syndrome giving the multiplicity and diversity of the symptoms complained
by the affected patients, which include nocturnal chocking, snoring, and unrefreshing
sleep, alongside the breathing abnormalities seen during sleep such as obstructive
apnoeas (OSAS), oxygen desaturations and arousals from sleep.  Sleep apnea severity is
usually assessed by the apnea-hypopnoea index (AHI), which is the number of complete
(apneas) or incomplete (hypopneas) obstructive events per hour of sleep.
OSAS is usually distinguished on the basis of occurrence of oxygen desaturations from
upper-airway resistance syndrome (UARS) in which there are neither apneas/hypopnoeas
nor oxygen desaturations in spite of a disturbed sleep due to arousals secondary to
increased work of breathing to overcome the increased airway resistance. 2
Epidemiology
The prevalence of OSAS varies according to different factors such as age, gender, body
mass index (BMI) and most of all severity of the disease and its related symptoms. Indeed,
according to the Wisconsin Sleep Cohort, one of the most important prospective
population-based studies on the natural history of sleep disordered breathing, the
prevalence of OSAS is about 24% in men and 9% in women aged 30-60 years of age
when using an AHI greater or equal than 5 events/hour as a diagnostic criteria.3
The prevalence of OSAS is slightly lower by combining sleep disturbances with associated
excessive daytime somnolence, being approximately 3% to 7% in adult men and 2% to 5%
in adult women.4
As mentioned above, OSAS has a tight association with obesity. In fact, the prevalence of
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OSAS is approximately 40% in moderately overweight men and raises up to 90% in
morbidly obese men (BMI > 40 kg/m2).5
Moreover, when data from the Wisconsin sleep cohort study were re-examined with
adjustment for overweight and obesity, a marked increase in the prevalence of OSAS was
observed (34% of men and 17.4% of women between the ages of 30-70 had an AHI ≥5). 6
These data reflect the worsening modern pandemic of obesity in western society which, as
a consequence, make the prevalence of OSAS likely to further increase in the next
decades.7
Indeed, obesity is not only the strongest risk factor for OSAS, but may also have an
important role on the pathogenesis of obesity therefore inducing a vicious circle.
Figure 1: determinants of sleep-disordered breathing and obesity.8
Obesity alters the normal upper airway mechanics and contributes to the pathophysiology
of OSAS in a number of ways (Figure 1): by the para-pharyngeal fat deposition which
results in a reduction in caliber and a change in shape of the upper airway promoting
collapsibility,9 by the reduction in lung volumes, especially functional residual capacity,
contributing to increased upper airway resistance,10 and by enhancing leptin
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resistance.11
Leptin is a hormone produced by adipocytes depending on their triglyceride content which
is involved in the suppression of appetite. It also acts on the central respiratory centres to
stimulate ventilation and its deficiency has been associated with hypoventilation. Indeed, in
mice lacking the gene encoding for leptin, a marked obesity was observed together with an
impaired hypercapnic ventilatory response during both wakefulness and sleep.12 Obesity-
induced leptin resistance can alter the response to hypercapnia leading to worsening of
the latter and impairment of arousal from sleep during apneas.
However, these important patho-physiological findings were confirmed by several clinical
studies such as the Sleep Heart Health Study, a multi-centre observational cohort study of
cardiovascular correlates of OSAS in middle-aged and older Americans.13
In this study a weight gain of 10 kilograms over a 5-year period conferred a 5.2- and 2.5-
fold raise in the likelihood of increasing the AHI by 15 events per hour in men and women
respectively.
OSAS is more frequent in men compared to women 14, which is not only due to the
greater prevalence of obesity among males, but also to several other factors and in
particular hormonal changes. In fact, OSAS prevalence is higher in postmenopausal than
pre-menopausal women and and hormone replacement therapy in post-menopausal
women may protect against the development of OSAS. 15
Age is surely one of the other OSAS determinants: the prevalence of OSAS increases with
age in adults and this age-related increase may be attributable to parapharyngeal fat
deposition, lengthening of the soft palate and changes in other anatomic parapharyngeal
structures. 16
Genetic aspects
It has been shown that up to 40% of the risk of developing OSAS is genetically
determined.17
In fact, the prevalence of OSAS in first-degree relatives of patients with OSAS ranges from
22-84% with an odds ratio (OR) of a first-degree relative having OSAS ranging from 2 to
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46. 18
Anatomic risk factors for OSAS, such as obesity and upper airway soft tissue structure,
demonstrate familial aggregation.
Interestingly, a case-control study in a Scottish cohort identified a strong familial
component to OSAS and suggested that differences in facial structure were more
important than obesity in this regard.19
The volume of lateral pharyngeal wall, tongue and total upper airway soft tissue have a
significant level of heritability after adjusting for sex, age, ethnic background, craniofacial
properties and neck fat deposition.
A number of candidate gene associations have been investigated in OSAS including
apolipoprotein E4 (ApoE4), tumour necrosis factor (TNF), and angiotensin-converting
enzyme (ACE), but only one a TNF alpha polymorphism (TNFA rs1800629) was
significantly associated with OSAS under an allele frequency model.20
However, the literature on this topic is rapidly growing and giving that the vast majority of
the associations have been published in that last 5 years, it is likely that future studies will
be able to identify more genes associated with sleep-disordered breathing.
Pathophysiology
The pathogenesis of sleep-disordered breathing is rather complex as it involves multiple
mechanisms, which alter the patency of the upper airway.
The upper airway can be divided into three compartments: (I) the naso-pharynx (epi-
pharynx) whose function is mainly respiratory; (II) the oro-pharynx which has respiratory,
deglutitory and reflex functions; and (III) the laryngo-pharynx (hypo-pharynx) whose
functions include speech, swallow and respiratory function.
There are static and dynamic factors that contribute to the upper-airway patency. Among
the formers we can find surface adhesive forces which for instance promote contact of the
tongue with the mucosa of the oral cavity during nasal breathing.21 Mouth opening
potentially destabilizes the airway by freeing the mucosal attachments of the tongue and
soft palate and allowing these now freely moving structures to relocate posteriorly and
compromise the pharyngeal airway. Another important static element is the position of
neck and jaw: the latter in particular can narrow the upper-airway by moving the tongue
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backwards. This is frequently seen when patients are sleeping in the supine position as
gravity plays an additional role as well.22
Lastly, another important static factor is the tracheal tug: increasing lung volume causes a
caudal displacement of the intra thoracic trachea that, in turn, generates caudally directed
forces on the upper airway.23 
Dynamic factors include the upstream resistance in the nasal airway and pharynx :
conditions as mucosal congestion or nasal polyps can increase nasal airway resistance
during inspiration producing a more-negative inspiratory swing in pharyngeal intraluminal
pressure and consequently a reduction of pharyngeal cross-sectional area.
Another dynamic factor is the Bernoulli effect, which is defined by the conversion of energy
from static to kinetic caused by an increase in the velocity of airflow when cross-sectional
airway area decreases. This causes a decreased pharyngeal intraluminal pressure leading
to narrowing of the pharynx during inspiration.
During sleep the impact of static and dynamic forces varies as the neuro muscular drive
drops, and makes the muscles more collapsible, therefore further reducing the airway
patency.24
Figure 2: Simplified model of the ‘balance of forces’, factors that promote closure or 
patency of the upper airway.25
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Other than sleep, confounders such as age and gender do affect static and dynamic
factors. To make the picture even more complex, in pathologic conditions such as
hypervolemic status heart failure 26 or obesity,27 oedema and fat distribution can further
increase the size of  soft tissue structures surrounding the upper-airway.
To summarise the pathophysiology of OSAS there are forces that promote patency and
closure of the upper airway. Both are influenced by physiological and pathological
mechanisms and in patients with OSAS the so called “balance of forces” favours
obstruction, therefore causing repetitive upper-airway occlusion during sleep.(Figure 2) 
Clinical manifestations
The clinical features of OSAS can be divided into daytime and nighttime symptoms. (Table
1)
Table 1: clinical features of OSAS.
Daytime features Nighttime features
Excessive daytime sleepiness Witnessed apneas
Unrefreshing sleep Choking at night
Morning headaches Snoring
Dry mouth Sleep fragmentation
Decreased concentration Nocturia
Memory loss
Decreased libido
Irritability
The nocturnal (sleep-related) symptoms and signs are more specific for OSAS than those
expressed during diurnal wakefulness such as excessive daytime sleepiness, which is
usually the result of abnormal sleep regardless of the cause. The OSAS patient might
report symptoms of tiredness, fatigue, or drowsiness, rather than overt daytime sleepiness,
and nighttime features are more often complained by the bed partner.28
Snoring is one of the major features of OSAS as almost all patients with OSAS do snore,
at least according to their partners. In addition, complaint of snoring often precedes the
complaint of daytime sleepiness, and the intensity increases with weight gain and bedtime
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alcohol intake.29Among all daytime symptoms, daytime sleepiness or fatigue seem to be
the most common complaints in patients with OSAS.30
The manifestations of sleepiness can have subtle consequences (midafternoon
drowsiness during a group meeting leading to an occasional nap), severe consequences
(falling asleep while eating or talking), or catastrophic consequences (falling asleep while
driving).
Causes of sleepiness in OSAS patients are multifactorial. Nocturnal sleep disruption may
be secondary to repetitive abnormal breathing events leading to arousals or complete
awakenings in the middle of night or to early morning awakenings, with subsequent
complaints of insomnia and reduced total sleep time.
Diagnosis
The diagnosis of OSAS does include a comprehensive sleep evaluation which consist of a
sleep oriented history and physical examination, and findings identified by sleep testing.31
The first step is usually determining patients at high risk of OSAS (Table 2)
Table 2: risk factors for OSAS.
Obesity (BMI>35 kg/m2)
Congestive heart failure
Atrial fibrillation
Difficult to treat/resistant hypertension
Stroke
Type 2 diabetes
Nocturnal arrhythmias
Pulmonary hypertension
High risk driving population
Preoperative for bariatric surgery
These patients should undergo a sleep assessment in order to investigate the presence of
signs or symptoms of OSAS previously described. In particular, more attention should be
paid to excessive daytime sleepiness, its severity should be assessed by the Epworth
Sleepiness Scale.32 
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Table 3:  The Epworth Sleepiness Scale.
Situation Chance of dozing
Sitting and reading 0......1......2......3
Watching TV 0......1......2......3
Sitting inactive in a public place (e.g a theater or a meeting) 0......1......2......3
As a passenger in a car for an hour without a break 0......1......2......3
Lying down to rest in the afternoon when circumstances permit 0......1......2......3
Sitting and talking to someone 0......1......2......3
Sitting quietly after a lunch without alcohol 0......1......2......3
In a car, while stopped for a few minutes in traffic 0......1......2......3
The Epworth Sleepiness Scale (ESS) is a simple, self-administered, 8-questions
questionnaire, which allows patients to rate their degree of daytime sleepiness. (Table 3)
The ESS asks people to rate, on a 4-point scale (0 – 3), their usual chances of dozing off
or falling asleep in 8 different situations or activities that most people engage in as part of
their daily lives. The total ESS score is the sum of 8 item-scores and can range between 0
and 24. The higher the score, the higher the person’s level of daytime sleepiness.
The physical examination can be crucial as it can allow to identify some potential
removable causes of the disease. Particular attention should be paid to the presence of
obesity, signs of upper airway narrowing, or the presence of other disorders that can
contribute to the development or the consequences of OSAS. Features to be evaluated
that may suggest the presence of OSAS are summarised in Table 4. 33 
Table 4:  Physical examination findings suggesting OSAS.
increased neck circumference ( > 43 cm in men, > 37 cm in women)
body mass index (BMI) ≥ 30 kg/m2
modified Mallampati score of 3 or 4
retrognathia
lateral peritonsillar narrowing
macroglossia
tonsillar hypertrophy
elongated/enlarged uvula
high arched/narrow hard palate
nasal abnormalities (polyps, deviation, valve abnormalities, turbinate hypertrophy) 
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Following history and physical examination patients should be assessed with objective
testing as the severity of OSAS must be established in order to make appropriate
decisions for treatment.34
The gold standard for diagnosing OSAS is full in laboratory polysomnography (PSG) which
involves the measurements of severa l parameters overn ight such as:
electroencephalogram (EEG), electro-oculogram (EOG), chin electromyogram, airflow,
oxygen saturation, respiratory effort, and electrocardiogram (ECG) or heart rate (additional
recommended parameters include body position and leg EMG derivations). This test
allows the clinician to understand not only the severity of OSAS, as determined by the
apnea + hypopnea index (AHI) or respiratory disturbance index (RDI), but also the degree
of sleep fragmentation, the presence of other sleep disorders that often co exist such as
periodic limb movements, and the overall sleep architecture. (Figure 3)
Figure 3: Printout of a PSG trace of a patient with severe OSAS. The violet boxes
represent apneas, defined by the absence of flow for at least 10 seconds, and the
corresponding pink boxes the oxygen desaturations.
The diagnosis of OSAS is confirmed if the number of obstructive events (apneas,
hypopneas + respiratory event related arousals) on PSG is greater than 15 events/hr or
greater than 5/hour in a patient who reports any of the following: unintentional sleep
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episodes during wakefulness; daytime sleepiness; unrefreshing sleep; fatigue; insomnia;
waking up breath holding, gasping, or choking; or the bed partner describing loud snoring,
breathing interruptions, or both during the patient's sleep.35 OSAS severity is defined as
mild for RDI ≥ 5 and < 15, moderate for RDI ≥ 15 and ≤ 30, and severe for RDI > 30/hr. 31
Other accepted tools to diagnose OSAS are home testing with portable monitors (PM)
however, they should be performed only in conjunction with a comprehensive sleep
evaluation.31 A PM should, at a minimum, record airflow, respiratory effort, and blood
oxygenation.
Treatment
Treatment options should be discussed in the context of the severity of the patient's
OSAS, their risk factors, any associated conditions, and the patient's expectations. The
first step should always be patient's education. The patient should be made aware of the
impact of weight loss, sleep position, alcohol avoidance, risk factor modification, and
medication effects. Weight loss in particular should be the first treatment option in obese
patients as it has been demonstrated that a reduction in body weight is accompanied with
a reduction of the AHI.13
The best treatment option for patients with moderate severe OSAS is positive airway
pressure (PAP). First described by Sullivan in 1981,36 PAP provides pneumatic splinting
of the airway and is effective in reducing the AHI.37
PAP may be delivered in continuous (CPAP), bilevel (BPAP), or autotitrating (APAP)
modes and it can be applied through a nasal, oral, or oronasal interface during sleep.
CPAP has been proven to reduce OSAS symptoms and in particular daytime sleepiness,
improve quality of life and ameliorate haemodynamic parameters such as blood pressure
and heart rate. 34
Another treatment option, although less effective, are custom made oral appliances (OA)
that may improve upper airway patency during sleep by enlarging the upper airway and/or
by decreasing upper airway collapsibility (e.g., improving upper airway muscle tone).38
Mandibular repositioning appliances (MRA) cover the upper and lower teeth and hold the
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mandible in an advanced position with respect to the resting position. Tongue retaining
devices (TRD) hold only the tongue in a forward position with respect to the resting
position, without mandibular repositioning. OA are indicated in patients with mild disease
or in those who did not tolerate CPAP. Of utmost importance, CPAP adherence can be
very poor, as shown by several prospective studies.39
Lastly, in the recent years different research groups proposed electrical stimulation as a
mean to treat OSAS by activating the dilator muscles of the upper airway in order to
maintain it patent while asleep. 25 More specifically electrical stimulation through the
hypoglossal nerve stimulation leads to a significant reduction in the apnoea-hypopnoea
index and the oxygen desaturation index as demonstrated by the STAr trial recently
published. 40 However, there are similar results published from feasibility studies for
transcutaneous electrical stimulation.41
OSAS and hypertension
The relationship between OSAS and hypertension has been extensively studied and
although many studies had some methodological limitations, recently some large
population based studies have consistently shown that significant associations of
polysomnographically determined OSAS and hypertension, defined by blood pressure
thresholds or use of antihypertensive medication, remain after adjustment for potential
confounding factors. (Table 5)
Collectively, the relationship between OSAS and hypertension has been assessed with
state-of-the-art measurements in more than 9,000 men and women from the general
population, and results have been consistent.
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Table 5: Association of polysomnographically determined sleep-disordered breathing and
hypertension in four population studies. CI=confidence interval, AHI=apnea hypopnea
index. Odds ratios are all adjusted for age, sex, body mass index (BMI), neck
circumference, alcohol intake, and cigarette smoking.
STUDY DESIGN Odds Ratio* for Hypertension (95% CI)
N AHI CATEGORY
<1.0 1 TO 4.9 5 TO 14.9 15 TO 30 ≥30
1. Wisconsin Sleep Cohort Study,42 
state employees, ages 30 to 65 years, 
prospective, 4-8 years follow-up
709 1.0 1.2 (1.1-1.8) 2.0 (1.3-3.2) 2.9 (1.5-5.6) —
2. Sleep Heart Health Study,43 
multicenter, ages 40-97 years
 a. Cross-sectional44 6132 1.0 1.1 (0.9-1.3) 1.2 (1.0-1.4) 1.3 (1.9-1.6) 1.4 (1.0-1.8)
 b. Prospective, 2- and 5-year 
followup43
2470 — 1.0 0.9 (0.7-1.2) 1.1 (0.8-1.5) 1.5 (0.9-2.5)
3. Southern Pennsylvania, population 
sample via random-digit dialing, ages 
20-100 years, cross-sectional45
1741 1.0 — 2.3 (1.4-3.6) 6.9 (2.0-
26.4)
—
4. Vitoria-Gasteiz, Spain, random 
census sample, ages 30-70 years, 
cross-sectional46
552 1.0 2.5 (1.1-5.8) 1.3 (0.5-4.1) 2.3 (0.9-5.7)
Figure 4: Pathophysiological mechanisms that link OSAS to the development of
hypertension.
18
Whilst the epidemiological data suggest a causal relationship between OSAS and
hypertension, a number of studies that have highlighted different pathophysiological
mechanisms summarised in Figure 4. 
Intermittent hypoxia, particularly if associated with episodes of intermittent re-oxygenation,
is one of the main mechanisms as it promotes the production of reactive oxygen species
(ROS), activates systemic inflammation, and ultimately impairs endothelial function. 
Endothelial dysfunction can be defined as an imbalance between vasorelaxation and
vasoconstriction substances produced by the endothelium.47 Previous studies have
demonstrated the strong association between endothelial dysfunction and OSAS even in
cases of mild disease.48
Nitric oxide (NO), the most important vasodilatory molecule synthesized by the
endothelium, is reduced in patients with OSAS.49
Moreover, repetitive cycles of hypoxia/reoxygenation stimulate the release of endothelin 1,
one of the most important vasoconstricting peptides. 50
The impact of CPAP on blood pressure
Recent studies have revealed that optimal CPAP control reduces BP, with more marked
effects in patients with resistant hypertension implying a role of the autonomic nervous
system in relation to changes in blood pressure.51
This reinforces the relationship between OSAS and hypertension as CPAP is the best
available treatment for this disease which is able to improve symptoms but also to restore
the haemodynamic balance.
Whilst the role of CPAP on blood pressure is well established, less is known about its
effect on blood pressure variability (BPV) giving that patients with OSAS exhibit also high
BPV.52
BPV is a marker of the autonomic nervous system and an independent predictor of
cardiovascular morbidity and mortality.53 It is defined as the fluctuation of BP between
different measurements over a defined time interval.54 Visit-to-visit BPV comparison is
related to an increased risk of cardiovascular events.55
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We aimed to investigate how CPAP treatment may modify the risk of increased
sympathetic activation, through its impact on BP and BPV, while comparing normotensives
and hypertensive patients with obstructive sleep apnoea. 
Patients with a diagnosis of OSA, and who had been referred to a tertiary sleep centre
(Sleep Disorder Centre, Guy’s & St Thomas’ Hospitals, London, UK), were enrolled
between, June 2013 to December 2013. 
OSA was diagnosed with a 4% oxygen desaturation index (ODI) > 5/hour combined with
excessive daytime sleepiness (ESS>10). The study was approved by the local institution’s
ethical board (2014/3081) and all patients gave written informed consent. 
Hypertension was defined according to the current guidelines,56 In order to investigate
any differential impact of CPAP, OSA patients where divided in 2 subgroups: patients with
a known diagnosis of hypertension or a BP greater that 140/90 mmHg on three occasions
were included in the hypertensive subgroup, patients with BP <140/90 mmHg on three
occasions were included in the normotensive subgroup. 
Following baseline recording of demographic data and BP measurements patients
underwent nocturnal pulse oximetry and were provided with an APAP device for home
use. At 2-week follow-up compliance data were obtained and and BP was measured
again, BPV was calculated.
At baseline, participant’s age, sex, height, weight, body mass index (BMI) and Epworth
sleepiness scale (ESS), as a measure of daytime sleepiness,32 were recorded.
At baseline and at 2-week follow-up, three blood pressure measurements each were
taken, with 1-minute intervals, using an automatic sphygmomanometer (Mindray VS-800,
Medical International Limited, Shenzhen, China). Patients were rested (>5 minutes), and
seated in an upright position. 
The average of pulse rate, systolic and diastolic BP was calculated from these readings.
Systolic and diastolic range was calculated as the difference between the maximum and
minimum BP values. 
Systolic and diastolic BPV was calculated as the standard deviation (SD) of the 3
measurements. 
All data were compared between baseline and 2-week follow-up (following APAP
treatment), this included delta (difference in) systolic and diastolic BP range,
means/average BP and SD; in addition to delta pulse.
Following baseline measurements, patients were issued with an auto-titrating continuous
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positive airway pressure device (APAP, S8/S9, ResMed Ltd, Sydney, Australia) for 2
weeks of home use. 
The following compliance and treatment indices were downloaded, and calculated:
average daily APAP usage (h), days of APAP usage >4 hours per day (n), days of APAP
usage <4 hours per day (n), percentage of days of APAP usage > 4 hours per day (%), air
leak (L/min) and the 95th percentile of APAP to control respiratory events (cmH2O).
The primary outcome parameter was change in BPV between baseline measurements and
at 2-weeks of treatment. Secondary outcomes included change in pulse rate, change in
absolute BP values, and comparison of these parameters in patients with and without
hypertension. Lastly, we compared patients with good CPAP compliance, defined as
CPAP usage greater than 4 hours per night for at least 70% of the total days, and sub-
optimal CPAP compliance to determine whether BPV changes were dependent on CPAP
usage.
Data were analysed using SPSS statistics 21 (IBM, New York, NY, USA) and tested for a
normal distribution using the Shapiro-Wilk normality test. Normally distributed data are
presented as mean (SD), and analysed with paired and unpaired t-tests. Non-normally
distributed and are presented as median (IQR), and analysed with the Wilcoxon Rank sum
test when paired, and the Mann-Whitney U test when unpaired. 
Correlation analysis was used to describe correlations between continuous independent
and dependent variables. 
Where bivariate analyses revealed significant correlations, logistic regression  analyses
were employed to identify independent correlations with the BPV parameters. BPV was
inserted as the dependent variable in the multivariate analysis with age, gender, BMI,
APAP compliance as independent variables. A sub-analysis compared BPV in patients
with optimal and sub-optimal APAP compliance. Non-normally distributed data were log-
transformed prior to regression analysis and comparison. A level of significance was
defined as p<0.05. To understand the significance of the difference found on BPV pre and
post treatment we performed a power calculation giving a significance level (adjusted for
sidedness) of 0.025, the total number of patients and the obtained difference in means of
1.2 mmHg. The calculated power was 99 percent that the study would detect a difference
at a two-sided 0.05 significance level, if the true difference between treatments is 1.200
times the standard deviation. 
We recruited a total of 78 participants with OSA: 76.9% males, BMI 36.2±6.9 kg/m2, age
49.0±12.9 years. At baseline, the systolic and diastolic BP was 130.9±15.5 mmHg and
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82.7±10.4 mmHg, respectively. Oximetry data confirmed severe sleep-disordered
breathing with a mean 4%ODI of 27.4±19.9 x hour -1 and a mean 3%ODI of 33.4±20.3 x
hour-1, whilst average oxygen saturation was 93.9±3.2, and baseline Epworth sleepiness
scale was 11.3±7.6 points (table 6). 
Thirty-eight participants had hypertension, 17 (45%) were untreated, 13 (34%) were
treated with angiotensin receptor blockers, 3 (8%) with beta blockers, 12 (32%) with
calcium channel blockers, 5 (13%) with diuretics and 1 (3%) patient with alpha-adrenergic
blockers. 
The hypertensive group (n=38) was older with mean age 51 (16.5) vs 43 (13) years,
p=0.008, and had a higher BMI 37.3 (8.0) vs 32.8 (8.9) kg/m2, p=0.019, than the
normotensive OSA group (n=40). No other baseline differences existed between the two
groups (table 7).
Table 6: BP parameters pre and post 2 weeks of APAP treatment in all individuals (n=78;
hypertensive and normotensive participants with OSA, BP=blood pressure, APAP=autoset
continuous positive airway pressure, OSA=obstructive sleep apnoea, SD=standard
deviation, ODI=oxygen desaturation index). Data presented as median (IQ range) unless
stated otherwise.
Pre-APAP Post-APAP p-value
Systolic BP(mmHg) 130.9 (15.5) 129.9 (14.9) 0.486
Diastolic BP(mmHg) 82.7 (10.4) 82.2 (10.5) 0.615
Systolic SD (mmHg) 5.3 (4.9) 4.2 (3.4) 0.049
Diastolic SD (mmHg) 2.0 (2.1) 2.3 (2.0) 0.410
Systolic Range (mmHg) 10.0 (8.8) 8.0 (6.8) 0.04
Diastolic Range (mmHg) 4.0 (4.0) 4.0 (4.0) 0.483
Pulse rate (bpm) 78.0 (14.5) 75.5(15.8) 0.033
Nocturnal Pulse rate (bpm) 70.0 (8.8) 69.7 (8.7) 0.416
Pulse rise index (h-1) 39.0 (20.4) 41.3 (19.6) 0.703
Nocturnal oxygen sat (%) 93.9 (3.2) 94.3 (3.1) 0.993
3% ODI (events/hour) 26.8 (28.4) 35.6 (29.7) 0.841
4% ODI (events/hour) 20.6 (27.0) 28.3 (26.3) 0.675
Epworth Sleepiness Scale (points) 11.0 (10.8) 7.5 (8.0) <0.001
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Table 7: Baseline characteristics and OSA severity of patients with and without hypertension.
(OSA=obstructive sleep apnoea, ESS=Epworth sleepiness scale, BMI=body mass index,
ODI=oxygen desaturation index). Data displayed as median and interquartile range; and group
differences are analysed with the Mann-Whitney U test, unless indicated otherwise.
Parameter HTN (n=38) NTN (n=40) P-value
Sex (% male) 71.0% 82.5% 0.367
Age (y) 51.0 (16.5) 43.0 (13.0) 0.008
BMI (kg/m2) 37.3 (8.0) 32.9 (8.9) 0.019
ESS (pts) 12.0 (10.0) 10.0 (11.25) 0.960
3% ODI (ev/h) 33.2 (31.9) 22.0 (19.2) 0.121
4% ODI (ev/h) 25.1 (29.6) 17.9 (16.5) 0.114
Mean Oxygen Saturation (%) 93.5 (3.6) 94.2 (2.9) 0.162
All 78 patients were seen at 2 weeks for follow up. No drop-outs were recorded. For all
patients, there was a significant reduction in symptoms, as measured by the ESS from
baseline 11.0±10.8 to follow up 7.5 ±8.0 points (p<0.001).  The 95th percentile APAP was
13.3±5.0 cmH2O and air leaks were acceptable (at 95th percentile 0.30±0.60 L/sec). APAP
was used for 14.0±0.0 days and the daily APAP usage was 3.0±2.3 hours. 41.0 % of
patients used APAP for more than 4 hours per day and the total hours of APAP usage
over 14 days was 43.3±31.4 hours. 
There were no differences in compliance data when comparing the hypertensive and
normotensive groups. 
Blood pressure variability as expressed by systolic BP standard deviation (5.3±4.9 to
4.2±3.4, p=0.049), pulse rate (78.0±14.5 to 75.5±15.8, p=0.033) and systolic BP range
(10.0±8.8 to 8.0±6.8, p=0.040) decreased compared to baseline. There was no difference
in absolute BP (systolic and diastolic), diastolic SD or diastolic range (table 6). 
A significant change in pulse rate was observed in the hypertensive OSA cohort (p=0.026),
but not within the normotensive cohort (p=0.471). A sub-analysis of patients did not show
any impact of compliance on changes of BP or BPV in the two groups but revealed a
greater change in the pulse rate (0.02±8.92 vs -4.44±6.72 bpm, p<0.05) in the group with
higher APAP compliance.
We found that delta mean systolic BP was associated with increased APAP pressure.
(r=0.293, p=0.009) and a delta BPV (systolic standard deviation) was inversely associated
with an increased APAP 95th percentile leak (r=-0.237, p=0.048). A decrease in pulse rate
(delta pulse), after compared to before APAP treatment, was correlated with: an increased
number of days where APAP was used for >4hours (r=-0.408, p<0.0001), a decrease in
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the number of days where APAP was not used (r=0.334, p=0.003), an increased total
hours used (r=-0.355, p=0.002), and an increased average daily usage (r=-0.352,
p=0.002). Regression analyses did not find any one of these APAP compliance measures
to independently predict a delta pulse.
When comparing patients with optimal and suboptimal CPAP compliance, there was no
difference in the change of the BP, but a reduction in the pulse rate in patients with optimal
compliance: -5.50±(8.25) vs -0.50 (10.50) bpm; p<0.05).
In this study, two-weeks of continuous positive airway pressure (APAP) treatment have a
beneficial effect on BPV in patients with OSA. This effect seems to occur through
modulation of blood pressure variability in the hypertensive patients, most likely due to an
improved sympathetic-vagal balance.
These results indicate that short-term treatment of OSA with CPAP treatment has a
favourable impact also on BPV.
As seen in this study there are many determinants which can impact on blood pressure
and blood pressure variability in patients with OSAS treated with CPAP. As discussed
previously CPAP treatment can not only treat apneas and therefore reduce the increased
sympathetic activation responsible for high blood pressure. Indeed CPAP can also cause
sleep disruption, reduced sleep efficiency and increased sleep arousals if the treatment is
not well managed and in particular if the CPAP pressure is not correctly titrated, if the are
too many leaks or if either the mask or the pressure is creating discomfort rather than
allowing a good sleep. Also compliance plays an inevitable huge role as roughly a quarter
of patients on CPAP stop its usage within weeks57 and at one-year follow up less than
half of the patients continue with regular use.58
This is of interest because symptoms amelioration and potential benefit on blood pressure
depend on tolerance and adherence to treatment.
In obese subjects in particular, the load on respiratory system is greater than in lean
subjects as CPAP pressure is greater which consequently increases the potential leaks
causing sense of breathlessness and imparied breathing at night.
Neural respiratory drive (NRD), as measured by the electromyogram (EMG) of the
diaphragm or using a surrogate marker, the parasternal EMG,59 reflects the load on the
respiratory system and is closely associated with breathlessness.60
We therefore performed a study in obese patients with OSAS that were studied in supine
posture while awake to determine the point at which CPAP maximally offloads the
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respiratory system, as determined by the lowest level of NRD and breathlessness. We
hypothesized that the effective nocturnal CPAP level differs from that required to
maximally offload the respiratory system while awake which could results in
breathlessness, impaired blood pressure control and affect long-term compliance. 
Obese subjects (>18years) with a body-mass index (BMI) above >25kg/m2 and confirmed
OSA were recruited from the Sleep Disorders Centre at Guy’s & St Thomas’ NHS
Foundation Trust, London, UK. The study was approved by the local Research Ethics
Committee and informed written consent was obtained from each patient.
Patients were fully evaluated by an expert sleep physician and were included if they had
either an apnoea-hypopnea index (AHI) >15/h, or if they were symptomatic (Epworth
Sleepiness Scale >10 points) and had and AHI >5/h. Anthropometric measurements
included age, sex, height, weight, body mass index (BMI), neck, waist and hip
circumference, Mallampati score, and smoking history. The Epworth sleepiness scale was
administered before the overnight polysomnography on CPAP titration. Continuous BP
was measured with a beat-to-beat BP monitor (Finapres).
CPAP during the titration night was determined by expert sleep technicians, as defined by
the 95th percentile of CPAP level that was required to avoid upper airway occlusion (CPAP,
sleep). The next morning, the surface electromyogram of the parasternal muscles (EMGpara)
and abdominal muscles (EMGabdomen) was measured, as previously described.61 For
recording of the surface EMGpara, electrodes were placed on each side of the sternum 3 cm
from the midline in the second intercostal space; for the surface EMGabdomen, one electrode
was placed in the middle of a vertical line connecting the lower rib cage with the anterior
superior iliac spine, with the subject standing. The other electrode was placed
approximately 4–5cm anterior to that location using surface electrodes (Kendall Arbo, Tyco
Healthcare Neustadt, Germany). Patients were then asked to rest on a bed to measure
baseline breathing and titrate pressures, while awake.
Prior to any measurements, patients were asked to lie on a bed in a standardised supine
position (legs straight and uncrossed, hands by their side with their palms facing down,
and head/shoulders supported using a pillow so that the patient felt no effort to maintain
head and neck posture) for five minutes. The surface EMG (EMGpara; EMGabdomen) was then
recorded for three minutes at baseline (without interface). A further three minutes were
recorded with a CPAP mask on (ResMed Mirage Quattro full face mask, ResMed Ltd,
Oxfordshire, UK), open to air. After that, the surface EMG signal was recorded while the
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mask was attached to a CPAP machine (CPAP S8, Resmed Ltd, Oxfordshire, UK) and
CPAP levels were changed stepwise from 4cmH2O to 20cmH2O, using increments of
+2cmH2O, every level was recorded for at least 3 minutes. At the end of each level,
patients were asked to score their perceived degree of breathlessness on a modified Borg
Scale (mBorg) for dyspnoea (from ‘0’ to ‘10’ points, with higher numbers indicating more
breathlessness). The protocol finished either when patients had reached a CPAP of
20cmH2O for >3minutes or when they felt that the pressures were unpleasant or caused
breathlessness.
The EMG data were amplified and band-pass filtered between 20Hz and 1kHz (Yinghui
Medical Equipment Scientific Ltd, Guangzhou, China), saved and analyzed using
LabChart (Version 7.3.7, ADInstruments, Colorado Springs, CO, USA). Raw EMG signals
were converted to root-mean-square (RMS), and all of the RMS of EMG was normalized to
baseline RMS of the EMG recorded when the patients were breathing at rest, without
mask, in supine posture; the results were expressed as percent of baseline activity
(%EMG, baseline). The mean value of RMS (time constant 100ms) in the final minute of
each pressure level (0-20cmH2O) was calculated to define NRD. Following daytime CPAP
titration, the pressure that led to the lowest level of NRD, as defined by the surface
EMGpara, was marked (CPAP, awake); this value was compared with CPAP, sleep. 
Data were statistically analysed using SPSS (SPSS, Chicago, IL, USA). Following testing
for normality, Borg scale and surface EMG during CPAP titration in individual cases were
expressed as mean ± SD. A one-way ANOVA was applied when Borg scale and surface
EMG were compared to baseline and maximal pressures, respectively. CPAP, sleep and
CPAP, awake were compared using paired t-test, post hoc corrections were used for
multiple comparisons. Statistical level of significance was defined with a p-value <0.05. 
15 patients with a confirmed diagnosis of OSA were studied. The patients were middle-
aged and predominantly male (80%), and obese, with one patient being in the overweight
category (number 4). Two patients had mild (number 3 and 15) and all others had
moderate-severe obstructive sleep apnoea. Patients had relatively preserved lung
function, as expressed by the age, gender and height adjusted percent predicted (Table
8). Baseline BP was 131.0(10.2)/85.1(9.1) mmHg.
Table 8: Demographics of patients. The group was predominantly male, middle-aged, all
but two patients suffered with moderate-to-severe obstructive sleep apnoea. F:M female
and male participants.
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Subject (n) Age (years) Gender
(F:M)
BMI (kg/m2) AHI (h-1) FEV1 (L/
%pred)
FVC (L/
%pred)
FEV1/FVC
(%)
1 34 M 32.6 28 3.49 / 81 4.66 / 89 75
2 38 M 37.2 23 4.13 / 102 5.09 / 103 81
3 54 F 49.7 10.4 1.43 / 70 1.59 / 65 90
4 57 M 27.9 51.2 3.64 / 106 4.13 / 96 88
5 54 M 40.4 77.4 3.09 / 86 3.80 / 84 81
6 54 M 42.6 18.7 3.00 / 83 3.85 / 85 78
7 49 M 36.7 22.6 2.77 / 76 3.53 / 79 79
8 48 M 38.7 20 2.35 / 62 3.79 / 80 62
9 37 F 37.3 52 1.88 / 83 2.68 / 101 70
10 53 M 30.8 40 3.16 / 99 3.60 / 91 88
11 62 M 41.5 16.3 2.45 / 75 3.62 / 86 68
12 46 F 36.4 20 1.53 / 63 2.25 / 80 68
13 60 M 44.7 24.7 3.13 / 93 4.01 / 93 78
14 31 M 44.9 69.4 4.28 / 90 5.49 / 95 78
15 37 M 42.1 9 3.57 / 92 4.50 / 95 79
Mean 47.6 3:12 38.9 32.2 2.9 / 84.1 3.8 / 88.1 77.5 
SD 9.9 5.8 21.1 0.9 / 13.3 1.0 / 9.8 8.0 
All but one patient completed the study protocol until they had reached a CPAP level of
20cmH2O; subject number 2 stopped at 14cmH2O due to discomfort. Except for subject
number 13, we observed in all patients that increasing levels of CPAP offloaded the
respiratory system resulting either in a clear reduction of EMGpara from baseline and/or a
substantial increase once the pressure levels for optimal chest inflation, as defined in the
method section as CPAP, awake, had been exceeded. The effect of CPAP on EMGabdomen
was variable, but there was a clear tendency to recruit abdominal muscles with higher
pressures in 9/15 participants.
The optimal level of chest inflation, as defined in the method section as CPAP, awake,
achieved a reduction in EMGpara to 70.2±17.7% of baseline activity (p=0.026), which was
lower than at the beginning and at the end of the protocol (EMG para at CPAP of 20cmH2O
was 103.3±49.3 % from baseline). EMGabdomen was significantly lower at CPAP, awake
(93.8±9.3% of baseline activity, p<0.001) when compared to the EMG at the beginning of
the protocol (CPAP of 0cmH2O), at higher CPAP levels (20cmH2O) EMGabdomen increased
and became highly variable, with a coefficient of variation as high as 70%. When CPAP
pressures were increased above 6cmH2O patients slowly started to feel more breathless
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(Figure 5) and with CPAP approaching 20cmH2O the Borg scale was significantly higher
than at the beginning of the protocol, although there was a high variability with a coefficient
of variation of up to 95%. The comparison of CPAP, sleep vs CPAP, awake revealed
significant higher nocturnal pressures (p=0.026) and associated Borg scores (p<0.05). In
7/15 patients Borg scores increased when comparing mBorg at CPAP, awake vs CPAP,
sleep (subjects number 2-5, 9, 13-14), in the remaining 8/15 patients mBorg scores
remained either the same or fell slightly (subject number 15).
Figure 5: Box Whisker Plots for the whole cohort indicating the A) EMGpara and B) mBorg
score at 0cmH2O, CPAP, awake and maximal pressures of 20cmH2O. * p<0.05, ** p<0.01
BP (figure 6) and BPV increased with incremental CPAP (systolic BP r=0.960,p<0.001,
diastolic BP r=0.961,p<0.001; systolic BPV r=0.662,p=0.026; diastolic BPV
r=0.886,p<0.001). sEMGabdo correlated with both systolic (r=0.464,p=0.032) and diastolic
BP (r=0.747,p=0.009). 
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Figure 6: Relationship of incremental CPAP titration and blood pressure change (mean,
SEM) from baseline. BP systolic (grey), BP diastolic (black)
Abdominal muscle recruitment (sEMGabdo) increased with higher CPAP (r=0.782,
p=0.004); there was no correlation between sEMGpara and CPAP (r=-0.110,p=0.748).
CPAP level was associated with blood pressure changes irrespective of muscle
recruitment BPV (table 2). Abdominal EMG was associated with some of the blood
pressure variables, irrespective of parasternal muscle recruitment (table 2).
This is the first study that systematically measured NRD and breathlessness during CPAP
titration in obese patients with OSA while awake and related these findings to the effective
CPAP level (CPAP, sleep) required to maintain airway patency when asleep. CPAP
effectively offloads the respiratory system in obese subjects, when awake, and reduced
NRD by 30% during optimal chest inflation. Breathlessness is of no concern when NRD is
reduced. However, when CPAP was increased to higher pressures, NRD, as reflected by
activity of the parasternal intercostal and expiratory muscles, increased and patients
became breathless. Moreover, CPAP led to an increase of both BP and BPV and this was
associated with EMG changes at different pressure.
This is of clinical interest giving that patients on CPAP are likely to stop the treatment the
longer the intervention. More interestingly, measuring EMG activity can help understanding
who is going to benefit more in terms of BP and BPV reduction. 
OSAS and the autonomous nervous system
OSAS is known to be related to a dysregulation of the autonomic nervous system (ANS)
and of the catecholaminergic metabolism although the pathophysiology of these
alterations is not fully understood. 
The repetitive episodes of complete or partial obstruction of the upper airway during sleep
lead to oxygen desaturations which trigger the so called “oxygen-conserving reflex” that
restores normoxia by promoting hyperventilation.62
This process generates a hyperactivation of the sympathetic nervous system that
mediates vasoconstriction to redistribute oxygenated blood flow to vital organs. At the
same time the parasympathetic nervous system  is activated with consequent bradycardia
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in order to reduce myocardial oxygen demand. 63 Once normal breathing resumes,
venous return and cardiac output increase, but the increased cardiac output is delivered
into a highly constricted peripheral vasculature, resulting in increase of BP at the end of
each apnoea. 
This physiologic response becomes pathological when the enhanced sympatho-excitation
is sustained over years, as is the case in OSAS. This phenomenon may be responsible of
the “non-dipping”  BP profile at night, which has been associated with an increased risk of
cardiovascular events. 
These hemodynamic and autonomic changes are not confined to nighttime: Elmasry and
colleagues showed that, in a population-based sample of hypertensive males (n = 116),
OSAS was associated with increased urinary concentrations of extraneuronal metabolites
of CAs, when compared to subjects without OSAS. This association was independent of
major confounding factors (age, BMI and severity of hypertension), suggesting an
increased sympatho-adrenal activity. 64
Treatment with CPAP for 4 weeks only has also been associated with a reduction in urine
normetanephrine excretion,65 however data emerging from other studies and clinical trials
have revealed a substantial variability regarding CPAP treatment and its effects on CAs
levels.66 This is presumably due to the complexity of the cathecolamine metabolism.
Catechol-O-methyltransferase (COMT) is one of the major mammalian enzymes involved
in the metabolic degradation of catecholamines. (Figure 7)
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Figure 7: Enzymes involved in catecholamines metabolism.
COMT was discovered by the Nobel prize Julius Axelrod in 1957 67 who showed that this
enzyme introduces a methyl group to the catecholamine, which is donated by S-adenosyl
methionine, and this process is mediated by Mg2+ as a catalyst of electron exchange and
inhibited by Ca2+. Any compound, either endogenous or exogenous, having a catechol
structure, like catecholestrogens and catechol-containing flavonoids, are substrates of
COMT.
However, giving that COMT metabolises also dopamine, it has been extensively studied
for the treatment of Parkinson disease. Less is known about the role of COMT in
catecholamine metabolism with regards to the development of hypertension and other
cardiovascular disorders.
COMT gene is located on chromosome 22, it is transcribed into 2 different mRNAs (1.3kb
and 1.5kb). This is due to the presence of 2 different primers: P1 allows the transcription
and translation of the soluble form of the enzyme (S-COMT) whilst P2 allows the
transcription and translation of both the soluble form and the membrane bound form of the
enzyme (MB-COMT). 68(Figure 8)
There are many different polymorphisms of COMT gene: one of the most important ones is
the VAL158MET that is due to a G-to-A transition at codon 158 of the COMT gene,
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resulting in a valine-to-methionine (V158M) substitution.69 This genetic polymorphism
results in a 3- to 4-fold reduction in COMT activity in red blood cells and hepatocytes which
results in a reduced methabolisation of catecholamines. This polymorphism doesn't modify
the kinetic characteristics of the enzyme as it doesn't involve the catalytic domain.70
Interestingly, this polymorphism was associated with individual variation in COMT thermal
instability. This is presumably due to a greater tendency to oxidation, as it is reverted by
adding dithiothreitol, a small-molecule redox reagent.
Figure 8: COMT location on chromosome 22 and the transcription into 2 isoforms of the 
enzyme.
The world population allele frequency is 37% for the mutated allele and 63% for the wild
type however, in the European population the frequency can reach 50%. 71 
There are also other important single nucleotide polymorphisms (SNP) such as Rs6269-
A/G, Rs4633-C/T (His62His) and Rs4818-C/G (Leu136Leu).72 These have been grouped
into 3 major haplotypes (table 9). 
Table 9: COMT major SNP and the different haplotypes.
Activity SNP
rs6269 rs4148 rs4680 rs4633
high + + + -
medium - - - +
low - - + -
A study has analysed the kinetics of COMT and found that it is dependent on the isoform
and the substrate: MB-COMT has a greater affinity but a lower O-methylation capacity of
32
catecholamines when compared with S-COMT. In fact, S-COMT Vmax is greater than MB-
COMT whilst Km is lower.73
These differences show that in cases of low substrate concentration MB-COMT activity will
be greater whilst in cases of high substrate concentration, MB-COMT contribution to O-
methylation will be less significant compared to S-COMT. During in vitro studies, usually
very high substrate concentrations are used compared to physiologic catecholamine
concentrations, leading to an underestimation of MB-COMT contribution to catecholamine
metabolism.
COMT is widely present in many different organs and tissues in humans. (Figure 9)
Figure 9: distribution of COMT enzyme in humans.
Giving the high interest in neurological disorders it has been extensively studied in the
central nervous system however, when compared with other organs (e.g. peripheral
tissues), mRNA levels, COMT quantity and activity are rather low. Also, COMT is more
prevalent in the choroid plexus, frontal cortex and cerebellum whilst in the nigrostriatal
pathway is less present.74
The highest COMT activity has been seen in the liver where is 2-3 fold greater than in
kidneys. 75COMT activity has been seen also in spleen, beta and delta pancreatic cells,
uterus, mammary glands, prostate and chromaffin cells of adrenal glands.
Sub-cellular localisation has been extensively studied in cerebral and cerebellar cortex:
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COMT has been found in neurons, dendrites and astrocytes mainly at the pre synaptic
level. 76
Interestingly COMT activity seems to be greater in men than in women. 77
Also, it varies with age: when measured in the liver, COMT activity increases up to 10
times from birth up to 50 years and then starts declining after 60 years of age.78
Giving the importance of COMT in the metabolism of catecholamines it is of interest also in
the pathophysiology of arterial hypertension. Catecholamines regulate blood pressure via
a central and peripheral pathway. 
In particular the arterial baroreflex, one of the body's homeostatic mechanisms that helps
to maintain blood pressure at nearly constant levels, is mediated by the sympathetic
nervous system. 
The baroreflex provides a rapid negative feedback loop in which an elevated blood
pressure reflexively causes the heart rate to decrease and also causes blood pressure to
decrease. Similarly, decreased blood pressure decreases baroreflex activation and causes
heart rate to increase and to restore blood pressure levels.
This important reflex acts also peripherally by activating alpha adrenergic receptors which
mediate vasoconstriction.79
Imai and colleagues 80 demonstrated that hypertensive rats had a blunted response to
noradrenaline release secondary to hypotension stimulus. 
After the administration of S-Adenosyl methionine a marked hypotension and increased
levels of normetanephrine were observed, due to the activation of COMT. 
Tsunoda and colleagues 81 showed that MB-COMT levels were reduced in hepatocytes of
hypertensive rats but this finding has not been replicated in the kidney, confirming that
there is a significant difference of COMT activity and quantity in different organs and
tissues. 
To conclude, the role of COMT in the development of hypertension is still debated. Giving
the complexity of catecholamine metabolism and the different variable involved (mutations,
isoforms, possible inhibitors) it is important to better understand whether the inhibition of
COMT is a predisposing factor to the development of hypertension. 
More importantly, it is crucial to understand the role of intermittent hypoxia, one of the
main features of OSAS, as a possible triggering factor of COMT activity.
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OSAS and catecholamine metabolism
We tried to demonstrate that during apneas patients with OSAS exhibit an activation of the
catecholaminergic system. We also wanted to understand whether COMT activity was
triggered by hypoxia and to what extent. 
Lastly we wanted to demonstrate that during sleep apneas patients with OSAS also exhibit
an activation of the endothelin and renin angiotensin aldosterone system, an increase of
the acute inflammatory indices and derangement of insulin secretion, which are all
associated to an increased cardiovascular risk.
We enrolled patients referred to either the Hypertension clinic or the ENT clinic services
(both Hospital of Padua, Italy) for assessment of suspected OSAS. 
All patients were provided with a patient information sheet and informed written consent
was obtained prior to enrolment. This study was approved by the hospital ethics
committee. (Number 3217/AO/14)
Patients of both genders (age 18 ≥ and ≤ 70 years) were eligible if they had:
• Symptoms and/or signs suggestive of OSAS (except craniofacial
dysmorphism and oropharyngeal abnormalities) such as obesity (BMI > 29
kg/m2), neck circumference (> 43 cm in men and > 41 cm in women),
daytime sleepiness, impaired concentration, morning headaches, nocturnal
chocking; 
• Overnight monitoring demonstrating an AHI > 5 events/hour during sleep.
• Patients with clinical evidence suggestive of OSAS and for which a DISE
was  needed to better investigate the site of obstruction. 
• Patients able to provide written informed consent.
Exclusion criteria were:
• Secondary hypertension;
• Treatment with beta-blockers;
• Decompensated diabetes mellitus type I and II;
• Pregnancy;
• Life expectancy < 2 years 
• Hemodynamic instability severe enough to require intravenous positive
inotropic agents;
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• Comorbidity conditions limiting the execution of DISE;
• Acute coronary syndromes (NSTEMI or STEMI) within 4 weeks; 
• Unwillingness or inability to complete follow up;
• Patient with any serious medical condition, which in the opinion of the
investigator, may adversely affect the safety of the participant;
• Known history of unresolved drug use or alcohol dependency;
• Current enrolment in another investigational drug or device trial.
All patients were screened to exclude a secondary hypertension diagnosis within the
previous 5 years by means of plasma aldosterone and renin after an appropriate wash-
out,82 urinary 24 hours catecholamines and metanephrines; moreover, when appropriate
patients underwent renal artery duplex, and adrenal CT or renal arteries CT angiography.
All subjects enrolled in the study underwent a full medical assessment where past medical
history and current medications were recorded. Also physical examination was performed
and antrophometric data were recorded. Excessive daytime sleepiness was evaluated
through the Epworth Sleepiness Scale (ESS). 32Before being booked for DISE all patients
underwent an attended cardio respiratory monitoring (CRM) to confirm the diagnosis of
OSAS, an ambulatory blood pressure monitoring (ABPM) and blood tests. (Figure 10)
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Figure 10: flow chart of the study.
Cardiorespiratory monitoring (CRM) was performed with an Embletta X 100 (Rembla,
Natus, Pleasanton, CA 94566 USA) which has previously been validated for patients with
suspected OSAS.83
Measurements obtained included nasal pressure, airflow by thermistor, respiratory effort
by impedance plethysmography, sonography, and finger pulse oximetry. The Embletta
devices were programmed to automatically begin recording at 22:00 and stop at 06:00.
Based on sleep logs and out of centre sleep testing (OCST) actigraphy (an intrinsic
component of the Embletta system), the scoring technologist modified the analysis start
time and end time, resulting in a TRT that attempted to approximate total sleep time (TST)
as closely as possible. Respiratory events (apneas and hypopneas) were scored
according to the American Academy of Sleep Medicine (AASM) Scoring Manual.84 
In particular, an apnea was defined if there was a drop in the peak signal excursion by ≥
90% of pre-event baseline and the duration of the ≥ 90% drop in sensor signal was ≥ 10
seconds. A hypopnea was defined when the peak signal excursions dropped by ≥ 30% of
pre-event baseline and the duration of the ≥ 30% drop in signal excursions was ≥ 10
seconds, and there was ≥ 3% oxygen desaturation from pre-event baseline or the event
was associated with an arousal.
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The apnea-hypopnea index (AHI) was calculated as the total number of apneas plus
hypopneas divided by the hours of sleep.  OSAS was defined when the AHI was greater
than 5 events per hour. Patients with significant central sleep apnea (> 5% of events) were
excluded.
Ambulatory blood pressure monitoring (ABPM) was performed using Spacelabs 90207
(SpaceLabs, Washington, USA). The between measurement intervals were 15 min
(daytime) and 20 min (night-time). During each recording, subjects were required to attend
at their usual daily activities, only refraining from unusual physical exercise or behavioral
challenges. Patients were also asked to mark on a diary their main activities, including the
time of meals, bed rest or sleep and awakening times. Only recordings rated as of
sufficient quality, i.e. including at least 70% of valid readings over the 24 h and at least two
valid readings per hour during daytime and one valid reading per hour during nighttime,
were considered for the final analysis. Day and night periods were defined and corrected
according to what reported by the patient in the diary. The average daytime period was
finally identified as the interval from 0800 h to 2300 h and the night period as the interval
from 2300 h to 0800 h. All procedures were performed according to current guidelines. 85
From each recording we calculated: the average 24-h, day and night systolic (SBP) and
diastolic (DBP) blood pressure; the degree of nocturnal BP fall and the standard deviations
(SD) of the mean of all individual readings over the different time periods considered. 
Based on the degree of nocturnal BP fall, subjects were classified as dippers (BP fall ≥
10% and <20% of daytime average BP) or non-dippers (fall<10%), separately for SBP and
for DBP. A subgroup of dippers with BP fall ≥ 20% were identified as extreme dippers.
The blood tests performed included: full blood count, C-reactive protein (CRP), serum
creatinine, blood urea nitrogen (BUN), serum ions (Na+, K+, Ca2+), glycaemia, HbA1c,
lipid profile, plasma catecholamines, PTH e vitamin D, fibrinogen, prothrombin time (PT)
and partial thromboplastin time (PTT), thyroid stimulating hormone (TSH), thyroxine (FT4),
serum cortisol, adreno-corticotropic hormone (ACTH), plasma aldosterone concentration
(PAC), plasma renin activity (PRA).
Also further metabolic and endothelial markers were studied: oxidized low density
lipoproteins (oLDL), endothelin 1 (ET-1), pro ET1, interleukin 2 (IL2), interleukin 6 (IL6),
tumor necrosis factor alpha (TNFα), interferon gamma (IFNγ), metalloproteinase,
nitrotyrosine, myeloperoxidase (MPO), neutrophil gelatinase-associated lipocalin (NGAL).
Also urinary tests were performed: urinary albumin excretion (UAE), urinary catecholamine
38
and metanephrine, 24h-urinary ions (Na+, K+, PO43-, Ca2+) and urinary isoprostanes.
Drug induced sleep endoscopy (DISE) was performed by an experienced otolaryngologist
in a semi dark and silent operating room with the patient lying supine in a hospital bed. The
whole procedure was performed according to the current guidelines.86 
Figure 11: Timing of blood tests performed before during and after DISE.
Drug-induced sleep was achieved with intravenous administration of propofol with a target-
controlled infusion rate after an initial loading dose. 
The electrocardiogram, blood pressure, and oxygen saturation were continuously
monitored by both the surgeon and the anesthesiologist. A flexible endoscope was used to
sequentially observe the nasal cavity, nasopharynx, velum, oropharynx, tongue base, and
epiglottis. 
During DISE, blood tests for cathecolamines and ET1 were performed as per Figure 11.
In particular after propofol infusion T0 blood test was performed. Afterwards, at the
occurrence of the first obstructive apnea, T1 was performed and then airway was kept
patent through mandibular protrusion manouver performed by either the surgeon or an
expert nurse. Then T2, T3 and T4 were performed when the patient was breathing
normally without any upper airway obstruction. Oxygen saturation (including minimum
SpO2 after the first apnea), heart rate and blood pressure were recorded throughout the
procedure.
Blood samples were collected using a syringe through a previously placed intravenous line.
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Samples were stored in Vacutainers containing EDTA as anticoagulant. Within 1 hour,
samples were centrifuged (4 °C, 2,500 rpm, 15 min). Afterwards plasma was transferred in
1,5 mL tubes and stored at -20°C.  Buffy coat (500 µL) was also stored at -20°C. Lastly,
red blood cells (400 µL) were transferred in a 1,5 mL tube, 200 µL of RIPA buffer was
added and vortex briefly. When lysis was complete, tubes were left on ice and eventually
stored at -80°C.
COMT activity was performed with the Nissinen and Mannisto method 87 using 3,4-
Dihydroxybenzylamine (DHBA) which is a catecholamine analog as a substrate, to obtain
vanillic and isovanillic acid. These metabolites were then analysed and quantified with
High Performance Liquid Chromatography (HPLC).
Buffer solution (400 µL) contained: phosphate buffer preparation (pH 7,4 250 mM) to keep
pH levels within the normal range in order for the enzyme to remain active, MgCl2 6.25
mM as a catalyst of electron exchange, SAM 2,5 mM as a methyl group donor and DHBA
0,5 mM as a substrate. The enzyme reaction was started by adding 200 µL of the red
blood cell lysis solution to the buffer solution and incubated for 45 minutes at 37°C. Tubes
were then placed on ice and HClO4 4M (150 µL) was added to obtain protein precipitation.
Tubes were then centrifuged at 10,000 rpm for 15 minutes at 4°C and supernatant was
collected and transferred to new 1,5 mL tubes and stored at -80°C for further quantification
of vanillic acid by HPLC method.
In the HPLC analysis, the reaction products (vanillic and isovanillic acid) in the supernatant
were analyzed by HPLC with electrochemical detection (ECD). The chromatographic
system consisted of a solvent delivery system CLC300 (Chromsystems), a programmable
autosampler CLC200 (Chromsystems) and a ECD CLC100 (Chromsystems). A
Discovery® C18 HPLC column (15cm x 4.6 mm, 5μm, SUPELCO) at 25°C was used as
the analytical column. A glassy carbon working electrode was set at 0.90 V versus an
Ag/AgCl reference electrode. The sensitivity was set at 20 nA. The mobile phase consists
of the buffer disodium hydrogen phosphate (0.1 M) and EDTA (0.15 mM) methanol (80:20,
v/v), the pH was adjusted to 3.2 with phosphoric acid. The flow rate was 0.8 ml/min. The
injection volume of the standard solution and the supernatant was 20 μL. COMT activity
was expressed as pmol of vanillic acid /min/mg prot. The analytical performance of the
method developed met the requirements of the FDA for bioanalytical method validation
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidan
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ces/ucm070107.pdf. Accessed 2010)
Protein measurement was performed using Quantum Protein kit (Euroclone, Milan, Italy)
which  is a formulation based on bicinchoninic acid (BCA) allowing a rapid identification of
protein content.
The BCA assay relies on the formation of a Cu2+-protein complex under alkaline
conditions, followed by reduction of the Cu2+ to Cu1+. The amount of reduction is
proportional to the protein present. The absorbance at 562 nm is then recorded and the
protein concentration is determined by comparison to a standard curve.
The assay has been performed diluting the lysis solution 1:500. 100 µL of the diluted lysis
solution was then transferred to a new 10 mL tube.
50 parts of reagent A were added to 1 part of reagent B provided in the Quantum Protein
kit.  2 mL of the mixture of reagents were then transferred to the tube containing 100 µL of
lysis solution and were incubated at 37°C for 30 minutes. Absorbance at 562 nm was
measured with a spectrophotometer uv visible.
All the samples used for calibration curve have been managed similarly.  Calibration curve
have been performed with a standard albumin solution 1mg/mL, progressively diluted in
order to get different concentrations (0,05-0,1-0,25-0,5 e 1 mg/mL).
All measurements have been performed twice.
At a two-sided 0.05 significance level a total of 12 patients will be required to have a 90
percent probability to detect an increase of endothelin-1 after DISE completion compared
to 5 minutes before its start if the true difference is 4.0 pg/ml. This is based on the
assumption that the within-patient standard deviation of endothelin-1 is 3.75 pg/ml (Paired
t – test). 88
Statistical analysis was performed using the SPSS statistical analysis programme (SPSS
17.0). Data are reported as median and interquartile range (IQR) as non-normally
distributed. 
COMT activity between different time points has been compared using Wilcoxon Signed-
Rank test. A p < 0.05 was considered to be statistically significant.
Statistical analysis was performed using SPSS (version 23 for Mac, IBM, Italy).
Thus far we screened 15 patients, 6 of which met all inclusion criteria and underwent
DISE.
There was only one female and the median age was 48 years. They were almost all
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overweight with a waist hip ratio of 1 (0.10). Only 2 patients out of 6 had symptoms of
excessive daytime sleepiness. Physical cardio pulmonary examination was unremarkable
in all subjects but 2, who had a systolic bruit. One patient had mild leg swelling with no
signs of decompensated heart failure or deep vein thrombosis. Two patients had severe
visual airway occlusion as represented by a Mallampati score of 4. Main characteristics
are shown in Table 10.
Table 10: Demographic and anthropometric characteristics of the enrolled patients. Data
in the last column are presented in median and inter quartile range (IQR) for continuous
variables. ESS=Epworth Sleepiness Scale. UoM=Unit of measure.
Patient  ID Age Sex BMI Neck size Waist Hip Waist-hip ratio ESS Mallampati
UoM years Kg/m2 cm cm cm points
001 48 F 40.83 124 140 0.89 11 4
002 45 M 29.89 45 103 101 1.02 8 1
003 48 M 22.59 35.2 90 89 1.01 13 2
004 48 M 25.38 37 86 100 0.86 9 4
005 73 M 27.64 43.5 103 102 1.01 7 2
006 48 M 27.78 27.8 107 107 1 1 2
MEDIAN 48 27.71 37 103 101.5 1 8.5
IQR 0 3.42 8.3 12.75 5.5 0.1 3.2
Past medical history showed that all patients had hypertension either untreated (1 subject)
or on antihypertensive medications (2 patients on angiotensin receptor blockers, 3 on ACE
inhibitors, 2 on diuretics and 2 on calcium channel blockers). Two out of six patients had a
prior diagnosis of coronary artery disease, 1 had dyslipidemia but no history of stroke,
atrial fibrillation or myocardial infarction was reported. Only one was a former smoker
whilst 3 were ex smokers. Of note, one subject had been diagnosed with restless leg
syndrome but was not on any medication.
Family medical history was positive for hypertension in 5 out of 6 subjects and no clear
features of secondary hypertension was noticed on physical examination.
Laboratory blood tests revealed that full blood count was normal among all patients, 2
patients had an elevated fasting glucose but only in one patient this was accompanied by
an elevated HbA1c. One patient had an impaired renal function and 4 patients out of 6 had
low vitamin D levels. (Table 11)
Table 11: Laboratory data of the enrolled patients. Data in the last column are presented
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in  median and inter quartile range (IQR) for continuous variables. e-GFR was calculated
with the MDRD formula. UoM=Unit of measure.
Patient  ID Hb Creatinine e-GFR HbA1c glucose Chol. tot Na K Vit. D
UoM g/dL umol/L ml/min/1.73m2 mmol/mol mmol/L Mg/dL mmol/L mmol/L nmol/L
001 13.3 48 127 50 6.6 156 139 3.2 62
002 16.3 84 91 40 5.1 234 137 4.2 53
003 13.7 82 92 33 5.1 210 141 4.3 88
004 16.2 67 117 34 4.4 127 140 4.3 56
005 15.8 90 76 36 6 164 141 3.8 81
006 13.1 121 59 34 5.2 176 139 4.8 44
MEDIAN 14.7 83 91.5 35 5.15 170 139.5 4.25 59
IQR 2.7 17.5 31 5 0.7 43.5 1.75 0.4 22.5
Hormonal laboratory tests showed normal thyroid function among all patients. Two
patients had slightly increased parathyroid hormone levels and this was presumably
secondary to low vitamin D levels in both patients and impaired renal function in one
patient. (Table 12)
Table 12: Hormonal data of the enrolled patients. Data in the last column are presented in
median and inter quartile range (IQR) for continuous variables. UoM=Unit of measure.
DRA= direct renin activity, PAC= plasma aldosterone concentration, TSH=thyroid
stimulating hormone, T4=thyroxine, PTH= parathormone, ACTH= Adreno Cortico Tropic
Hormone.
Patient  ID DRA PAC TSH T4 PTH Cortisol ACTH
UoM mlU/L pmol/L mlU/L pmol/L ng/L nmol/L ng/L
001 350.5 383 1.12 14.65 19.3 271 20
002 811 201 1.37 17.54 33 252 11
003 47.3 116 1.16 15.66 17.8 250 17
004 12.1 67.5 1.08 15.59 15.6 46 6
005 25.2 246 1.16 19.4 18.7 315 27
006 30.2 265 1.8 18.13 33.5 428 23
MEDIAN 38.75 223.5 1.16 16.6 18.9 261.5 18.5
IQR 248.25 123 0.18 2.37 11.5 53.5 9.75
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Three patients had increased renin activity but this was not associated with increased
aldosterone concentrations. Cortisol levels, measured at 8 in the morning, and ACTH
levels were within normal limits in all patients. Blood pressure profiles are shown in table 9.
Four patient had high office blood pressure, however 24 hours blood pressure profile was
within normal limits for 5 patients out of 6. Of note 4 patients had a non dipping blood
pressure pattern.
Table 13: Office and ambulatory blood pressure data of the enrolled patients. Data in the last column are
presented in median and inter quartile range (IQR) for continuous variables. All variables were measured in
millimetres of mercury (mmHg)
OFFICE AMBULATORY
Patient  ID SBP DBP SBP (24h) DBP (24h) SBP (day) DBP (day) SBP (night) DBP (night)
001 151 91 120 69 124 73 103 52
002 129 91 125 83 128 87 117 72
003 122 81 118 76 120 77 114 72
004 143 91 119 75 121 78 112 67
005 159 87 141 79 140 79 142 79
006 117 72 121 77 125 80 108 67
MEDIAN 136.3 89 120.5 76.5 124.5 78.5 113 69.5
IQR 25.5 8.5 4.75 3.25 5.5 2.5 7.25 5.75
Polysomnographic data confirmed obstructive sleep apnea in all subjects: only one had 
severe OSAS, the majority had mild-severe OSAS. (Table 14).
Table 14: Polysomnographic data of the studied patients. Data in the last column are 
presented in either median and inter quartile range (IQR) for continuous variables. 
UoM=Unit of measure.
Patient  ID TRT AHI Mean SpO2 N obs. apneas N hypopneas
UoM min Events/hour %
001 316.7 21 94.1 30 82
002 444.1 22 94.7 47 119
003 414.1 9.3 94.9 3 61
004 447.6 30 92 112 123
005 404.8 29.1 93.4 127 69
006 431.2 13.5 96.8 67 30
MEDIAN 422.6 21.5 94.4 57 75.5
IQR 33.7 11.9 1.2 66.5 46.7
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Urinary data did not show relevant abnormalities: sodium 24 h secretion was increased in
2 subjects and calcium secretion was within normal limits. Catecholamines secretion was
also normal even when adrenaline and noradrenaline urinary secretion was considered.
(Table 15)
Twenty-four-hour urinary albumin excretion (UAE) was normal in all subjects not
suggesting renal damage.
Table 15: Urinary data of the enrolled patients. Data in the last column are presented in
either median and inter quartile range (IQR) for continuous variables. UoM=Unit of
measure.
Patient  ID Methanephrine Methanephrine 24h Normetanephrine Normetanephrine 24h
UoM nmol/L nmol/24h nmol/L nmol/24h
001 0.1 0.18 0.14 0.25
002 0.08 0.09 0.27 0.39
003 0.06 0.13 0.1 0.22
004 0.11 0.24 0.08 0.18
005 0.03 0.08 0.13 0.33
006 0.09 0.22 0.11 0.26
MEDIAN 0.08 0.16 0.12 0.25
IQR 0.03 0.11 0.03 0.08
DISE was completed in all subjects without any complications.
Propofol was used for sedation either as boluses (4 subjects) or given via a continuous
infusion after a loading dose (2 subjects). The median propofol dose per procedure was
150 (75) mg and the number of boluses ranged between 2 and 3. In three patients
sevoflurane was employed as additional anaesthetic and in 2 patients fentanil was used
for analgesia. Blood pressure at the start of the procedure was 155/77.5 (17.5/8.5) mmHg
and at the end was 120/67.5 (22.5/12.5) mmHg.
Four patients had a propofol-induced central apnoea at the beginning of the procedure.
One patient did not have any obstructive apnea during the procedure but only an
hypopnea with a lowest oxygen saturation of 87%.
After propofol administration, COMT activity reached a peak at 134.6 [87.7 – 141.2]
pmol/min/mg and a second peak was observed 2 minutes after the obstructive apneic
event. (Figure 12)
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Figure 12: COMT activity during sleep endoscopy in the different stages for all subjects.
Data are expressed as median and IQR.
Figure 13: COMT activity during sleep endoscopy in subjects with the propofol induced
central sleep apnea. The star stands for a significant reduction (p<0.05) between T 0 and
T 1. Data are expressed as median and IQR.
No statistical significance was seen when we compared COMT activity for the different
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time points, however, when we considered only the four subjects who had a central apnea
after propofol administration the peak was more marked. Indeed COMT activity at T0 was
181.2 (12.8) pmol/min/mg and at T1 99.4 (11.1) pmol/min/mg (p<0.05) (Figure 13)
Figure 14: average COMT activity during sleep endoscopy in a subject with no relevant
desaturations during the procedure.
Furthermore, in one patient who did not have relevant apnoeas during the procedure no
changes of COMT activity were seen throughout (Figure 14).
COMT activity seemed to be influenced by age as the oldest patient (73 years old) had the
lowest activity when measured at baseline before the procedure (55.6 pmol/min/mg).
In one patient without the propofol-induced central sleep apnea and with an obstructive
event reaching a minimum oxygen saturation of 88% a peak of COMT activity was seen
after the first apnea.  
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Figure 15: COMT activity in a subject without the central event induced by propofol but
with an obstructive even reaching a minimum oxygen saturation of 88%.
Figure 16: average COMT activity and adrenaline concentration during sleep endoscopy
in a subject with an initial central sleep apnea propofol-induced.
COMT activity returned to baseline values after 30 seconds from the obstructive event.
(Figure 15) In one patient we analysed adrenaline concentration at each time-point. Figure
16 shows that a higher COMT activity corresponds to lower adrenaline levels.
In order to understand whether propofol itself could exert an inhibiting or stimulating effect
on COMT activity we incubated red blood cells of a healthy subject (age 24 years, BMI
25.1 kg/m2) with propofol. COMT activity was analysed at baseline, after 5, 10 minutes
48
and one hour. The experiment was repeated twice to correct for analytic errors.
The results are showed in figure 17. A slight decrease of COMT activity was seen
throughout. However, when considering the time frame of 5 minutes, the change was less
relevant.
Figure 17: COMT activity in red blood cells of a healthy subject incubated with propofol.
Red and blue lines are representing the same experiment repeated twice.
We further wanted to understand the type of COMT enzyme in red blood cells as we know
that the kinetics of COMT is dependent on the isoform and the substrate: MB-COMT has a
greater affinity but a lower O-methylation capacity of catecholamines when compared with
S-COMT.73 
These differences in activity between the two isoforms show that in cases of low substrate
concentration MB-COMT activity will be greater whilst in cases of high substrate
concentration, MB-COMT contribution to O-methylation will be less significant compared to
S-COMT. 
We therefore performed Western blot on red blood cell lysis solution of the first three
patients enrolled. (Figure 18)
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Figure 18: Western blot for patient 001, 002 and 003. Arrow represents the two bands
corresponding to the two COMT isoforms (yellow arrow MB-COMT, red arrow S-COMT).
M=marker. 
Other than the 2 bands corresponding to the two isoforms (26 e 30kDa, MB and S-COMT
respectively), there were two more bands visible with a molecular weight of 50-60 kDa. 
We initially hypothesised, giving that the additional bands had an increased molecular
weight by 2-fold, that this could be a dimer because there are seven cysteine residues in
human S-COMT which can then create disulfide bridges.
This hypothesis needs to confirmed by further experiments, however studying COMT
activity in red blood cells is rather complex because of haemoglobin interferences but most
of all because COMT quantity is lower when compared with other cells (eg. Hepatocytes).
Moreover, we did not see 50-60 kDa bands when performing western blot in haepatocytes
and macrophages (data not shown). This is intriguing as dimers could be a sort of
reservoir of the enzyme which can be activated in conditions of high demand.
COMT dimers have been already observed both in humans and rats,83 however their role is
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still controversial.
An analysis of the dimers by gel-permeation chromatography revealed an equilibrium with
monomers that could be accelerated by increased temperature. The activation energy for
the monomer–dimer transition must therefore be rather small, which also explains the
large variations in dimer content that was observed for different protein preparations.89
The preliminary data of our study on the first 6 subjects showed that the cathecolaminergic
system is stimulated during DISE in patients with OSAS.
COMT activity is increased after propofol administration more markedly if a central apnea
occurs, conversely a less relevant increase in COMT activity was seen after the first
obstructive event. COMT activity does not seem to be influenced by the anaesthetic agent
used and an increase in COMT activity is associated with lower plasma adrenaline levels.
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Discussion
This series of studies aimed to better understand the changes of the autonomous nervous
system and blood pressure in patients with OSAS. This is of crucial importance giving that
not all patients with OSAS develop hypertension and cardiovascular complications and,
similarly, not all patients benefit from CPAP also in terms of blood pressure and
sympathetic hyperactivity correction.
The World Health Organization states that cardiovascular diseases are the first cause of
death globally and that most of them can be prevented by addressing behavioural risk
factors such as tobacco use, unhealthy diet and obesity, physical inactivity and harmful
use of alcohol using population-wide strategies.90
Obesity is one of the most serious public health challenges of the 21st century as the
worldwide prevalence has nearly doubled between 1980 and 2008.91
As obesity is associated with OSAS the same trend of increasing prevalence has been
demonstrated for the latter.
In fact, the prevalence of OSA was 4% of middle aged men and 2% of middle aged
women in the United States in the early 1990’s,3 but with the obesity epidemic the
prevalence now reached 10% for 30-49 year-old men and at 3% for 30-49 year-old women
in the US.6
Thus, OSAS represents other than a sleep disorder a huge public health issue and
understanding the pathophysiology behind its association with hypertension and
cardiovascular events is of crucial importance. 
In this series of studies we aimed to understand firstly the haemodynamic changes that
occur in patients with OSAS and, most of all, if treatment with CPAP can be of help and to
what extent. 
Whilst the association of OSAS and hypertension has been extensively proved, much
more complex is demonstrating that CPAP treatment exerts a beneficial effect not only on
symptoms, but also on high blood pressure. 
The latter has a prognostic value on cardiovascular events and this should be considered
when assessing patients with OSA and hypertension.92
There is evidence showing that assessing BPV is important when determining the overall
cardiovascular risk of a patient with hypertension. Rothwell et al have demonstrated that
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systolic BPV and maximal systolic BP are strong predictors of stroke, independent of the
mean systolic BP.53 An increased residual variability of the systolic BP in patients with
treated hypertension is associated with a high risk of vascular events; patients with OSA
are subjected to repeated surges of sympathetic nervous system activity93 which explains
their higher BPV.52 
The observed decrease in BPV in patients with OSA treated with APAP is accompanied by
a decrease in the pulse rate suggesting a beneficial effect of CPAP on the overall
sympathetic activation. Heart rate, represented by its surrogate pulse rate, can also predict
long-term BP changes in patients with OSA treated with CPAP and it could be evaluated in
prospective studies of patients with sleep-disordered breathing who are treated with CPAP
in clinical sleep services.
Supporting the findings that APAP might reduce BP parameters, systolic BP changes was
associated with an increased APAP pressure. Air leaks are associated with low CPAP
compliance, and indeed we found increased APAP leak reduced the effect of APAP
treatment on BPV. This suggests that mask leak could influence compliance and have an
indirect haemodynamic effect with a detrimental impact on BPV.  
When we compared subgroups with optimal and suboptimal compliance the decreases in
BPV parameters did not reach statistical significance, but this might be due to the small
sample size. However, optimal CPAP compliance was associated with a greater reduction
in pulse rate, suggesting a greater impact on sympathetic nervous system activation.
One of the main issues with CPAP is the poor adherence. In fact, depending on the
definition of compliance and the system used approximately a quarter of patients is non-
compliant after 6 weeks and more than half after 1-year.94
Patient discomfort plays an important role in patients' adherence and, particularly in obese
subjects, higher CPAP levels can increase the work of breathing, induce hyperventilation
and impair lung mechanics.
In fact, obese subjects breathe at low lung volumes.61 Employing CPAP to inflate the
chest, to stent the airway, abolishes intrinsic positive end-expiratory pressure (PEEPi) in
supine posture and shift the tidal volume to a more-favourable part on the pressure-
volume (PV) curve helping to improve compliance of the respiratory system, reducing the
work of breathing and NRD.95 
53
However, when pressures are increased so that the chest is inflated beyond a normal level
of functional residual capacity, the work of breathing increases again and this is reflected
in an increased EMGpara. This is associated with a raised sympathetic activation, which is
paralleled by an increased BP and BPV.
As a consequence, patients who have their effective CPAP level at pressures higher than
what is well tolerated when awake will experience discomfort and breathlessness. It is not
unlikely that patients who try to fall asleep, or wake up at night, feeling breathless because
of the high CPAP level will stop using the device in the long term. To address this problem,
a lower level of CPAP, potentially sub-therapeutic, might prove more beneficial than an
optimal CPAP setting with lower compliance. Furthermore, it would be of interest to
understand whether CPAP adherence and blood pressure control could be improved by
adjusting pressures according to the level of breathlessness and/or NRD. The fact that we
found different physiological responses with CPAP titration also raises the question on
what defines different phenotypes; the measurement of oesophageal and gastric
pressures could aid to understand what determines different responses. 
As described previously, modulations of the autonomous nervous system are common in
OSAS.96 Dimsdale et al. measured catecholamines in plasma and urine and found that
24-hours urinary norepinephrine levels were significantly higher in patients with OSAS
than in patients without OSAS (58.2 ng vs. 40.2 ng, p < 0.002), both during the day and at
night. 97
In fact, in OSAS patients, the repetitive apnoeic events lead to intermittent hypoxia (IH)
and CO2 retention, both of which can augment sympathetic nervous activity (SNA) via
stimulation of central and peripheral chemoreceptors.98
Triggered by the reduction in blood pressure and stroke volume during obstructive apnoeic
events carotid sinus baroreceptors also stimulate SNA. 
Indeed, the baroreflex provides a negative feedback loop in which elevated blood pressure
inhibits sympathetic outflow with ensuing decreased heart rate and blood pressure. On the
other hand, decreased blood pressure blunts baroreflex mechanisms, causing heart rate
increases, and blood pressure to rise.99 
A large amount of studies confirmed an increase in catecholamine levels in patients with
OSAS and showed also that CPAP treatment might effectively reduce catecholamine
levels.65 This make it plausible to exploit catecholamine levels in the blood or urine as a
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potentially viable biomarker of OSAS severity that can be used to monitor patients'
responses to treatment.66
Our hypothesis generating study speculates that COMT plays an important role in
metabolising catecholamines and in particular that its activity could be modulated by
intermittent hypoxia.
We showed that central apnea and the consequent oxygen desaturation is associated with
an increased activity of the enzyme which may well be related to a physiologic response to
preserve the blood oxygenation homeostasis.
The carotid body is a small chemosensory organ located at the bifurcation of the internal
and external carotid arteries that senses arterial oxygen partial pressure. Intermittent
hypoxia triggers signalling from the carotid body that activates the sympathetic nervous
system, leading to increased catecholamine secretion, which increases arterial tone, with
ensuing hypertension. 100
This process is presumably mediated by the Hypoxia Inducible Factor (HIF) as exposure
of Hif1a+/– mice and their wild type littermates to intermittent hypoxia for 10 days resulted
in marked increases in systolic and diastolic blood pressures and a significant elevation in
plasma norepinephrine concentration in the WT mice, whereas their Hif1a+/– littermates
are unaffected.101
If from a purely pathophysiological perspective, our study sheds some light on the
biochemical mechanisms that cause an increase in catecholamine levels in patients with
OSAS, from the clinical perspective it could help clinicians understanding which patients
with OSAS are more prone to develop hypertension, are at higher risk of developing
cardiovascular events, and therefore might benefit more the most from treatment.
Current guidelines suggest that a treatment is highly recommended for patients with
moderate or severe sleep-disordered breathing and symptoms of excessive daytime
sleepiness.37
However, for patients with mild or moderate disease, in particular with no relevant daytime
symptoms, there is no clear recommendation. This is of interest as the proportion of
patients with mild-moderate disease is relatively high and is at risk of cardiovascular
events. Although trials on patients with mild or moderate disease are lacking, Marin and
colleagues published prospective observational data on 403 patients with untreated mild to
moderate OSAS (AHI between 5 and 30) compared to 264 controls, and demonstrated a
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tendency toward increased fatal and non-fatal cardiovascular events in the patient group at
9 years of follow-up.102
Thus, measuring COMT activity might identify OSAS patients with an impaired
catecholamine metabolism and presumably at risk of developing hypertension.
This approach has potential advantages compared to catecholamines use as a biomarker
in that their role for diagnosis of OSAS is not firmly established, most likely because of the
large amount of confounding factors and associated morbidities that frequently accompany
OSAS and can independently lead to changes in catecholamine levels. Indeed,
confounding factors such as age, hypertension, obesity, and the use of anti-hypertensive
medications are not easy to control for, thereby increasing the difficulty to interpret at the
individual patient level the real impact of OSAS on catecholamine levels.
One of the findings of this study is that a drug induced central apnea caused marked
changes in catecholamines and COMT activity. This is of interest because uncertainty still
exists as to whether we need to treat patients with central sleep apnea (CSA) to prevent
cardiovascular morbidity and mortality. 
Central sleep apneas and hypopneas arise from complete or partial reductions in central
respiratory drive during sleep that lead, respectively, to complete or partial cessation of airflow for
at least 10 seconds. Central apneas occur when PaCO2 falls below the threshold required to
stimulate breathing. A CSA disorder is present when central apneas and hypopneas occur
cyclically. CSA is often seen in the setting of heart failure (HF) due to a tendency to hyperventilate
so that PaCO2 repeatedly drops below the apnea threshold, usually after acute increases in
ventilation following arousals from sleep.77
Our findings are consistent with the work by Javaheri where among HF patients, CSA was
associated with greater sympathetic activation while awake than in those without sleep
apnea.78 However, unlike OSAS, no inspiratory efforts or negative intrathoracic pressure is
generated during central apneas so that they do not cause as great an increase in left
ventricular afterload. 
The purpose of this and future research is to understand what are the determinants that
modulate COMT activity and to what extent.  As previously discussed, COMT activity
seems to be greater in men than in women.60 Our findings confirm what is previously
known about the effect of age: COMT activity increases up to 10 times from birth up to 50
years and then starts declining after 60 years of age.78
As we noticed a significant increase of COMT activity after propofol administration we had
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to dismiss the possibility that the drug itself could alter the kinetic of the enzyme.
Propofol is the most important intravenous general anaesthetic in current clinical use. It
acts by potentiating GABA-A (γ-aminobutyric acid type A) receptors. The binding site has
been only recently discovered and is located within the β subunit at the interface between
the transmembrane domains and the extracellular domain.105
Of all the induction agents, propofol has the most profound cardiovascular depressant
effects. It causes the largest reduction in mean arterial pressure through a balanced
venous and arterial vasodilation, resulting in a reduction in both cardiac preload and
afterload. It also blocks the normal baroreceptor reflex-mediated tachycardia which would
typically accompany these changes, resulting in only small increases in heart rate. 
Propofol also causes profound respiratory depression, consistently producing apnea at
induction doses. At lower doses, such as those used for sedation, minute ventilation is
reduced, with decreases in tidal volume being larger than decreases in respiratory rate.
The ventilatory response to hypoxia and hypercapnia is reduced as well. 106
In our study we did not show a relevant inhibitory effect of propofol on COMT although,
when incubating red blood cells with propofol a low inhibitory effect was seen after one
hour.
In our study we could demonstrate an effect of hypoxia on COMT activity, which, as far as 
we are aware of, has never been reported in human beings.
In fact, Garvey and colleagues studied rats maintained under normal (normoxic) and high-
altitude, 3800 m, 13% PO2 (hypoxic) conditions. They showed that COMT activity at high
altitude was increased on the last days of gestation but depressed after birth, compared to
control levels. 107
However, intermittent hypoxia involves brief episodes of hypoxia followed by longer
periods of reoxygenation, whilst continuous hypoxia does not involve such fluctuations.
Although HIF-1 activity seems to be induced in both conditions, the mechanisms regulating
its activity under conditions of chronic hypoxia or intermittent hypoxia may differ.108
Thus, further studies are needed to understand the role of HIF in intermittent hypoxia with
regards to the development of hypertension in patients with OSAS.
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Conclusion
In this series of studies we described pathophysiological changes of blood pressure and
autonomous nervous system in patients with OSAS.
We demonstrated that CPAP treatment can not only treat OSAS symptoms and reduce
blood pressure, but can also modulate the autonomous nervous activity by reducing the
sympathetic discharge as seen by a reduction of blood pressure variability.
This can be achieved only if compliance is optimal. Also, other CPAP related factors such
as leaks and CPAP pressure might have a huge impact on the aforementioned
parameters. In fact, a higher pressure can overload the respiratory system leading to
patient discomfort, breathlessness, increased sympathetic discharge, and increased blood
pressure and blood pressure variability.
As the activity of the autonomous nervous system is mediated by the catecholaminergic
system we also showed it is stimulated during apnoeic events as seen during drug induced
sleep apnea. This might be due to an altered activity of COMT, one of the most important
enzymes involved in catecholamine metabolism, therefore suggesting a novel
pathophysiological pathway responsible of hypertension in patients with OSAS.  
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